Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-12-17
pubmed:abstractText
The purpose of this study was to investigate the vascular response of zotarolimus-eluting stent (ZES) and sirolimus-eluting stent (SES) using serial intravascular ultrasound (IVUS).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1097-6744
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
155
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
108-13
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:18082499-Aged, pubmed-meshheading:18082499-Angioplasty, Balloon, Coronary, pubmed-meshheading:18082499-Coronary Restenosis, pubmed-meshheading:18082499-Coronary Stenosis, pubmed-meshheading:18082499-Drug-Eluting Stents, pubmed-meshheading:18082499-Female, pubmed-meshheading:18082499-Follow-Up Studies, pubmed-meshheading:18082499-Humans, pubmed-meshheading:18082499-Male, pubmed-meshheading:18082499-Middle Aged, pubmed-meshheading:18082499-Probability, pubmed-meshheading:18082499-Reference Values, pubmed-meshheading:18082499-Risk Assessment, pubmed-meshheading:18082499-Sensitivity and Specificity, pubmed-meshheading:18082499-Single-Blind Method, pubmed-meshheading:18082499-Sirolimus, pubmed-meshheading:18082499-Survival Rate, pubmed-meshheading:18082499-Time Factors, pubmed-meshheading:18082499-Treatment Outcome, pubmed-meshheading:18082499-Tunica Intima, pubmed-meshheading:18082499-Ultrasonography, Interventional, pubmed-meshheading:18082499-Vascular Patency
pubmed:year
2008
pubmed:articleTitle
Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III.
pubmed:affiliation
Stanford University Medical Center, Stanford, CA 94305, USA.
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III